Stock Movers: Block, Progyny, Expedia (Podcast)

Block expects $12.3 billion in annual gross profit, above prior guidance and analyst estimates, with Q2 gross profit forecast at $3 billion, up 20% year over year. Progyny rose after strong Q1 results eased concerns about macro pressure on fertility demand. Expedia fell despite Q1 revenue of $3.43 billion, up 15% year over year and above consensus, after leaving full-year guidance unchanged.

Analysis

XYZ is the cleaner re-rating story here: the market is likely underestimating how much incremental gross profit leverage flows through once the business crosses a higher fixed-cost absorption point. The bigger implication is competitive rather than just company-specific — if management can credibly re-accelerate into Q2, smaller consumer-fintech peers with weaker unit economics will face a tougher funding environment as investors re-anchor on profitable growth instead of top-line momentum.

PGNY looks like a classic sentiment reset where operating data is improving faster than the perceived macro handicap. The second-order effect is that fertility demand may be more resilient to employment noise than the market model assumes, which should compress the risk premium across women’s health and elective-care names that trade as if utilization is one macro shock away from breaking. That creates room for both multiple expansion and a short-covering reflex if the next set of prints confirms stability.

EXPE is less about a demand miss and more about the market punishing a lack of upside torque in guidance. When revenue beats but full-year outlook stays fixed, the stock can de-rate because investors are paying for acceleration, not just resilience; that dynamic is a warning sign for other online travel platforms with similar mix and booking visibility. The key risk is that World Cup demand can skew the near-term read, so if Q2 strength doesn’t convert into better full-year cadence, the current selloff may only be the first leg.

The contrarian read is that the move in XYZ and PGNY may still be too early for consensus to fully trust: both names need one more quarter of confirmation before multiple expansion becomes durable. By contrast, EXPE may be closer to capitulation than a true fundamental break, because unchanged guidance after a solid beat often creates a cleaner setup for a later rebound if summer demand holds.

Key Decisions for Investors

• Go long XYZ on a 2-4 week horizon into the next earnings/guidance follow-through; favor call spreads over stock to capture upside while limiting downside if Q2 growth slips.
• Add to PGNY on weakness over the next 1-2 weeks; the setup favors a medium-term long if subsequent utilization data confirms macro resilience. Use a 3-6 month view with stop discipline if fertility volumes soften.
• Initiate a tactical short EXPE or buy puts for 1-2 months as a guidance-quality trade; the risk/reward is attractive if the market continues to punish lack of full-year upside, but cover if summer booking commentary turns incremental.
• Pair trade: long PGNY / short a higher-beta healthcare services peer with more macro sensitivity over 1-3 months, expressing the view that fertility demand is less cyclical than feared.
• If XYZ gaps higher again, trim into strength rather than chase; the near-term risk is that the market has already priced in the gross profit upgrade before operating leverage is fully proven.